Propoxycaine hydrochloride
Based on 1 publication(s) in Google Scholar
Propoxycaine hydrochloride is a voltage-gated sodium channel inhibitor. Propoxycaine hydrochloride delays monophasic A spike action potential recovery. Propoxycaine hydrochloride increases bulk lateral, rotational, and annular lipid fluidity in neuronal membrane lipid bilayers, with greater inner monolayer fluidization, and induces membrane protein clustering. Propoxycaine hydrochloride can be used for the research of pain.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.70%
- CAS 番号: 550-83-4
- 分子式: C16H27ClN2O3
- 分子量:330.85
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Propoxycaine hydrochloride
More
生物活性
製品説明
体外実験
Propoxycaine (1 mM; 5 min) hydrochloride, when combined with Procaine (HY-B0546), delays action potential recovery in isolated Rana pipiens sciatic peroneal nerves and produces a pronounced, prolonged Wedensky block[1].
Propoxycaine (0.01-1 mM; 30 min) hydrochloride increases lateral mobility of bovine cerebral cortex synaptosomal plasma membrane vesicles (SPMVs), with a greater effect on the inner monolayer than the outer monolayer[3].
Propoxycaine (0.01-1 mM; 30 min) hydrochloride increases annular lipid fluidity in bovine cerebral cortex SPMVs[3].
Propoxycaine (0.02-1 mM; 30 min) hydrochloride induces protein clustering in bovine cerebral cortex SPMVs[3].
Propoxycaine (0.01-1 mM; 30 min) hydrochloride increases rotational mobility of bovine cerebral cortex SPMVs, with a greater, selective effect on the inner monolayer[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 550-83-4
-
性状 Solid
-
分子量 330.85
-
分子式 C16H27ClN2O3
-
Color White to light brown
-
SMILES
O=C(OCCN(CC)CC)C1=CC=C(N)C=C1OCCC.[H]Cl
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Stem Cell Res Ther
Local anesthetics impair the growth and self-renewal of glioblastoma stem cells by inhibiting ZDHHC15-mediated GP130 palmitoylation. [Abstract]2021 Feb 4;12(1):107. PMID: 33541421
溶剤 & 溶解度
体外:
H2O : 100 mg/mL (302.25 mM; Need ultrasonic)
DMSO : 50 mg/mL (151.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: ≥ 100 mg/mL (302.25 mM); Clear solution
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. TRUANT AP, et al. Differential physical-chemical and neuropharmacologic properties of local anesthetic agents. Anesth Analg. 1959 Nov-Dec;38:478-84. [Content Brief]
[2]. TAINTER ML, et al. New local anesthetic solutions containing propoxycaine. J Am Dent Assoc. 1955 Jul;51(1):19-27. [Content Brief]
[3]. Lee JH, et al. The effect of propoxycaine.HCl on the physical properties of neuronal membranes. Chem Phys Lipids. 2008;154(1):19-25. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 3.0225 mL | 15.1126 mL | 30.2252 mL | 75.5629 mL |
| 5 mM | 0.6045 mL | 3.0225 mL | 6.0450 mL | 15.1126 mL | |
| 10 mM | 0.3023 mL | 1.5113 mL | 3.0225 mL | 7.5563 mL | |
| 15 mM | 0.2015 mL | 1.0075 mL | 2.0150 mL | 5.0375 mL | |
| 20 mM | 0.1511 mL | 0.7556 mL | 1.5113 mL | 3.7781 mL | |
| 25 mM | 0.1209 mL | 0.6045 mL | 1.2090 mL | 3.0225 mL | |
| 30 mM | 0.1008 mL | 0.5038 mL | 1.0075 mL | 2.5188 mL | |
| 40 mM | 0.0756 mL | 0.3778 mL | 0.7556 mL | 1.8891 mL | |
| 50 mM | 0.0605 mL | 0.3023 mL | 0.6045 mL | 1.5113 mL | |
| 60 mM | 0.0504 mL | 0.2519 mL | 0.5038 mL | 1.2594 mL | |
| 80 mM | 0.0378 mL | 0.1889 mL | 0.3778 mL | 0.9445 mL | |
| 100 mM | 0.0302 mL | 0.1511 mL | 0.3023 mL | 0.7556 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Propoxycaine hydrochloride 関連分類
HY-B1243 関連分類
Powered by Bioz
Keywords
- Propoxycaine
- 550-83-4
- Sodium Channel
- Wedensky block
- frog sciatic peroneal nerve
- dental operative anesthesia
- neuronal membrane lipid bilayers
- bovine cerebral cortex SPMVs
- membrane protein clustering
- dental surgical procedural anesthesia
- action potential recovery
- local anesthetic
- Rana pipiens
- Inhibitor
- inhibitor
- inhibit